Summary
This research project investigates the role of Nrf2 in beta cell expansion during pregnancy to understand its mechanisms and potential as a therapeutic target for gestational diabetes mellitus (GDM).
The role of Nrf2 in beta cell expansion during pregnancy
US · IL
National Institutes of Health
grant
awarded
#nih-7K01DK128387-04
What they want
The project will determine if in vivo loss- or gain-of-Nrf2 function affects beta cell proliferation, survival, mass, insulin secretion, and glucose homeostasis in pregnant mice, and if these alterations persist post-partum. It will also identify Nrf2 target genes in islets during pregnancy and assess Nrf2's necessity for pregnancy-mediated adaptive human beta cell proliferation in vivo. The overarching goal is to provide insight into how Nrf2 promotes functional beta-cell mass expansion during pregnancy and establish a platform for novel GDM therapeutic strategies.
Deliverables
- Determination of the role of Nrf2 on the expansion of beta-cell mass during pregnancy.
- Uncovering the mechanisms by which Nrf2 regulates beta-cell mass expansion during pregnancy.
- Testing if Nrf2 is necessary for pregnancy-mediated adaptive human beta cell proliferation in vivo.
- Insights into how Nrf2 promotes expansion of functional beta-cell mass during pregnancy.
- A basic platform for designing and testing novel therapeutic strategies for the treatment of GDM.
Market context
inferred from NAICSProfessional, Scientific & Technical Services
NAICS 541714
- US market size
- $2.0T
- Typical award
- $25K – $50M
Typical buyers
All federal civilianDoDStates
Commonly required
8(a)WOSBSDVOSBPE/PMP
Sector-level estimate — full code lookup not yet in catalog.
